Steven P. LaRosa, MD CV

 

CURRICULUM VITAE
Steven P. LaRosa, M.D.

Address                      23 Junction Lane

South Hamilton, MA 01982

Phone                         (401) 575-1812

Email                         slarosamd@gmail.com

THERAPEUTIC AREAS
Infectious Diseases

Pulmonary/ Critical Care
Coagulation

Inflammation/Immunology

Extracorporeal Devices

RESEARCH EXPERIENCE

Vice President, Clinical Development    Entasis Therapeutics, Mar 2020- present

§  Medical lead- Phase III trial of Sulbactam-Durlobactam in Carbapem-Resistant Acinetobacter baumannii infections

§  Safety Monitor- Phase III trial of Sulbactam-Durlobactam in Carbapenem-Resistant Acinetobacter baumannii infections

§  Medical Lead- Phase III trial of Zoliflodacin in Gonorrhea

§  Responsible for clinical development of ETX0282CPDP in cUTIs

§  Responsible for clinical development of ETX0462 for Pseudomonas aeruginosa

§  Interactions with BARDA/DTRA/Batelle for biodefense applications of ETX0462

§  Member-Business Development Team

     Ex-officio Chief Medical Officer            Microbion Corporation, Feb 2019 –Jan 2020

§  Worked with the internal team to secure a CARB-X grant for an aerosolized antimicrobial in Cystic Fibrosis

    Ex-officio Chief Medical Officer Epiphany Biosciences, June 2018 –Jan 2020

§  Developed a clinical development plan for an experimental antiviral in Zoster, Infectious Mononucleosis, Alzheimer’s Disease, Multiple Sclerosis and Glioblastoma Multiforme including study synopses

§  Developed pitch slide decks for each of the above indications

§  Participated in teleconferences with Venture Capital Companies, potential large Pharma partners, the NIH and NIA

§  Participated in teleconferences with 2 Nobel Laureates regarding the viral hypothesis of Alzheimer’s Disease

§  Successfully co-authored a publication that was published in a peer-reviewed journal outlining the evidence supporting the viral hypothesis of Alzheimer’s Disease

Event Adjudicating Committee     Pfizer 2015-Sep 2019

§  A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Staphylococcus aureus 4-antigen (SA4Ag) Vaccine in Adults Undergoing Elective Posterior Instrumental Lumbar Spinal Fusion

§  Performed blinded interpretations of all protocol-defined infections, cases of multi-organ system failure and causes of death

Data Monitoring Committee          Bristol-Myers Squibb 2015-2018

§  Phase Ib/2a Study – Anti-PD –L1 monoclonal antibody (BMS-936559) for Severe Sepsis

§  Performed unblinded review of all safety data and serious adverse events

Ex-officio Chief Medical     ExThera Medical 2011-2018
Officer

§  Designed in vitro study of CRE Enterobacteriaceae by mini covalently -attached heparin columns. Results successfully published in PlosOne

§  Designed in vitro study of CMV by mini covalently- attached heparin columns. Presented results in abstract session at Society of Critical Care Medicine (SCCM)

§  Contributed significantly to the protocol design of the “First in Human” Clinical Trial of SERAPH Extra-Corporeal Cartridge in patients with Staph aureus bacteremia

§  Performed safety review for all patients enrolled in first-in human clinical study

§  Contributed significantly to funded DARPA grant to study SERAPH cartridge in animal models of bacteremia

Senior Medical Advisor      Leading Biosciences, Inc. 2015-2016

§  Phase II study of oral Tranexamic acid in Septic Shock

§  Contributed significantly to creation of clinical study protocol

§  Contributed significantly to CRF

§  Participated in Site Selection

§  Significant participation in clinical site and CRO training at Investigator Meetings

Scientific Advisory Board Sciclone 2013-2014

§  Phase II study of Thymosin alpha in severe sepsis

§  Contributed significantly to design of Phase II protocol

§  Represented company at “face to face” meeting with the  FDA

 

     Senior Medical Advisor   Artisan/Asahi Kasei Pharma 2009-2013

§  A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients with Sepsis and Suspected Disseminated Intravascular Coagulation.

§  Advised CEO of a protocol amendment to the study that allowed it to be completed and demonstrated an efficacy signal

§  Participated as a co-author on a manuscript summarizing the clinical data from the study that was published in Critical Care Medicine

 

     Safety Monitor             Cardiome 2008-2010

§  Phase I Study of GEDI-102-ADS (Activated Protein C Variant) in Healthy Humans

§  Performed unblinded review of all data for healthy subjects dosed with molecule. Gave “go” or “no go” recommendation to Chief Medical Officer

 

    Medical Director          Ocean State Clinical Coordinating Center (OSCCC) 2004-2011

§  Co-founded this academic CRO at Rhode Island Hospital/ Brown Medical School for the purpose of partnering with Industry sponsors to direct Phase II and III trials in Severe Infection

§  Hired and managed a Project Manager, 3 Research Nurses, 3 Research Assistants and 2 Administrative Assistants (9 reports)

§  Worked with the Project Manager to produce SOPS that were ICH and GCP compliant

§  Effectively secured 5 grants over 11 years:

§  Clinical Coordinating Center for TFP008: Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Three-Arm Study to Evaluate the Safety and Efficacy of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor), a recombinant biologic ptrotein, Administration in Subjects with Severe Community Acquired Pneumonia. Project No. 6057; Sponsor: (originally Chiron Corp) Novartis Pharmaceuticals; Amount: $1,419.136; Term: April 1, 2004 to July 28, 2008; Co-investigator: Steven LaRosa, M.D.

§  Clinical Coordinating Center for E5564-G000-301: ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis. Project No. 7051; Sponsor: Eisai Medical Research Inc.; Amount: $4,033,397; Term: December 2005 to January 31, 2011; Principal Investigator: Steven LaRosa, M.D

§  Clinical Coordinating Center for LF-0801: A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis. Project 8905; Sponsor: Agennix Incorporated; Amount: $156,200; Term: March 1, 2008 to July 2009; Principal Investigator: Steven LaRosa, M.D.

§  Clinical Coordinating Center for A Multicenter, Randomized, Double-Blind, Placebo-controlled Phase IIb Study to Compare the Efficacy and Safety of Two or Three Dosing Regimens of Intravenous Infusions of CytoFabTM (AZD9773), a monoclonal antibody, in Adult Patients with Severe Sepsis. Project No. 9575; Sponsor: AstraZeneca Pharmaceuticals LP; Amount: $653,764; Term: November 1, 2009 to May 31, 2011; Principal Investigator: Steven LaRosa, M.D.

§  Clinical Coordinating Center for OASIS: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis. Protocol No. LF-0802; Sponsor: Agennix Incorporated; Amount: $1,558,017; Term: November 2010 to May 31, 2011; Principal Investigator: Steven LaRosa, M.D Collaborated with sponsors on development of the clinical study protocol

 

§  Collaborated with CROs of the development of the Case Report Form

§  Provided key input to CROs on site selection

§  Trained the investigators and CRAs from the CRO at Investigator Meetings

§  Maintained a 24/7/365 phone center for authorization of all subjects and to answer all site protocol questions and safety concerns thereby minimizing protocol violations

§  Developed and maintained a compliant database for recording all calls between the coordinating center and clinical sites

§  Held bi-monthly teleconferences with industry sponsors to review study progress and issues

Medical Advisor           Toray Medical 2001-2004

§  Advised this Japanese Company’s CEO and CMO on a clinical trial strategy for their Immobilized-Polymyxin extracorporeal filter (TORAYMYXIN) for Severe Sepsis in the USA

§  Represented the company at a face to face meeting with the FDA

Site Principal Investigator Eisai 2001-2004

§  Enrolled subjects at the Cleveland Clinic in the Phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist, in patients with severe sepsis

§  Chaired the Clinical Evaluation Committee (CEC) which performed a blinded adjudication of key study endpoints

Site Principal Investigator ICOS 2001-2004

§  Enrolled subjects at the Cleveland Clinic in Phase III study of Platelet Activating Factor Acetylhydrolase (PAFase) in Severe Sepsis

§  Participated in the Clinical Evaluation Committee (CEC) which performed a blinded adjudication of key study endpoints

Clinical Research Physician         Eli Lilly and Company 1998-2001

§  Within 3 months of being employed by the company was appointed the lead research physician for the worldwide Phase III registration trial (PROWESS) of Drotrecogin alfa activated (Xigris), a recombinant biologic protein, for severe sepsis

§  Performed a blinded analysis of subjects enrolled and determined that the trial was not enrolling a discriminatory population to demonstrate an efficacy signal

§  Collaborated on the Statistical Analysis Plan with the team statistician

§  Authored a protocol amendment to the study that was approved by regulatory agencies throughout the world

§  Conducted investigator meetings in 11 countries to implement the protocol amendment

§  The clinical trial was stopped early at the 2^nd interim analysis for overwhelming efficacy

§  Edited the Clinical Investigator Brochure and yearly safety update

§  Participated as an author the clinical trial manuscript published in the New England Journal Of Medicine

§  Presented the baseline characteristics of the PROWESS study at the annual Society of Critical Care Medicine meeting

§  Worked with the FDA to implement a Compassionate Use Program in patients with Purpura Fulminans

§  Participated in the pre-BLA meeting with FDA

§  Authored Sections of Biologic License Application submitted to regulatory agencies

§  Advised the company against the use of the name ZOVANT for the drug, This name was ultimately rejected by the FDA

§  Advised the company against discounting a treatment interaction based on disease severity.

§  Designed a Phase Ib study of Drotrecogin alfa activated in the human endotoxin challenge model

§  Collaborated with Thai investigators on a retrospective study of coagulation activation Human Septicemic Melioidosis

§  Evaluated in-licensing opportunities with Business Development

EMPLOYMENT HISTORY

Vice President, Clinical Development   Entasis Therapeutics, 03/23/2020- present

Attending Physician                                Division of Infectious Disease Beverly Hospital, Beth

Israel Lahey Health, 09/04/2012-03/20/2020

Medical Director                                    Antimicrobial Stewardship Program, Beverly

Hospital/Beth Israel Lahey Health, 09/04/2012-present

Division Director                                    Division of Infectious Disease, Scott and White

Healthcare, 06/27/2011-6/16/2012

Attending Physician                               Division of Infectious Diseases, Rhode Island Hospital,

04/15/2004-05/30/2011

Associate Staff Physician                        Department of Infectious Disease

Cleveland Clinic Foundation, 04/01/2001-03/31/2004

Clinical Research Physician                    Eli Lilly and Company 1998-2001

ACADEMIC APPOINTMENTS

Associate Professor of Medicine           Texas A&M Health Science Center, College of

Medicine, 06/2011-6/2012

Assistant Professor                                The Warren Alpert Medical School of Brown

of Medicine                                          University, 03/2004-05/2011

Clinical Assistant Professor of Medicine Clinical Assistant

Penn State University School of Medicine, 03/2001­03/2004 Internal Medicine, Hershey Medical School, 07/1995­06/1996

 

Clinical Assistant                                   Ohio State University of Medicine, 07/1995-06/1996

POSTGRADUATE EDUCATION

Fellowship                   Infectious Disease, Massachusetts General Hospital, Boston,Massachusetts, 07/01/1996­06/30/1998

Chief Residency        Internal Medicine, Cleveland Clinic Foundation,

Cleveland, Ohio, 07/01/1995-06/30/1996

Residency                  Internal Medicine, Cleveland Clinic Foundation,

Cleveland, Ohio, 07/01/1992-06/30/1995

EDUCATION

Medical School          Doctor of Medicine, Alpha Omega Alpha

Boston University School of Medicine
Boston, Massachusetts, 09/1988-05/1992

Undergraduate         Bachelor of Science in Biology, Magna cum laude

Boston College, Boston, Massachusetts, 09/1984-05/1988

MEDICAL LICENSE

Massachusetts – MD, 1996-1998, 6/20/2012 to present

ABIM BOARD CERTIFICATIONS

Internal Medicine through Dec 31, 2028
Infectious Disease through Dec 31, 2021

MEMBERSHIP IN SOCIETIES

Member                            Society of Critical Care Medicine (SCCM), 1998-present

Member                            Infectious Disease Society of America (IDSA), 1996-present

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1.      Gordon S, LaRosa S, Kalmadi S, et al. Should prophylaxis for pneumocystis carinii pneumonia in solid organ transplant ever be discontinued? Clin Infect Dis 1999; 28:240-246.

2.      Bernard GR, Vincent JL, Laterre PF, LaRosa SP, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344(10):699-708.

3.      LaRosa SP. Sepsis: menu of new approaches replaces one therapy for all. Cleve Clin J Med 2002; 69(1):65-73.

4.      LaRosa SP. Conflict of interest: Authorship issues predominate. Arch Intern Med 2002; 162.

5.      Singh-Behl D, LaRosa SP, Tomecki KJ. Tick-borne infections. Dermatol Clin 2003; 21:237-244.

6.      Opal SM, Garber GE, LaRosa SP, et al. Systemic host responses in severe sepsis analyzedby causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis 2003; 37:50-58.

7.      Dhainaut JF, Laterre PF, LaRosa SP, et al. The clinical evaluation committee in a large phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS). Crit Care Med 2003; 31:2291-2301.

8.      Kalil AC, Coyle SM, Um JY, LaRosa SP, et al. Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 2004; 21(3):222-229.

9.      LaRosa SP, Tomecki KJ. Antibiotics: What’s new. Cutis 2004; 73(1):10-14.

10.  LaRosa SP, Opal SM. Clinical trials of novel anticoagulants for severe sepsis: A tale of three molecules. Adv Sepsis 2004; 4(1):17-23.

11.  Padmanabhan R, LaRosa SP, Tomecki KJ. What’s new in antibiotics? Dermatol Clin 2005; 23(2):301-312.

12.  LaRosa SP, Opal SM. Tissue factor pathway inhibitor and antithrombin trial results. Crit Care Clin 2005; 21:433-448.

13.  Choure AJ, Shrestha RK, LaRosa SP, et al. Fever, chills, and chest radiographic infiltrates in a middle-aged woman. Cleve Clin J Med 2005; 72 (5):367-374.

14.  LaRosa, SP. Use of corticosteroids in the sepsis syndrome: What do we know now? Cleve Clin J Med 2005; 72(12):1121-1127.

15.  LaRosa SP, Opal SM, Utterback B, et al. Decreased protein C, protein S and antithrombin levels are predictive of poor outcome in gram-negative sepsis caused by Burkholderia pseudomallei. Int J Infect Dis 2006; 10(1):25-31.

16.  LaRosa SP. Drotrecogin alfa (activated) in severe sepsis. [comment]. N Engl J Med 2006; 354(1):94-96; author reply 94-96, 2006 Jan 5

17.  Soliman MM, Dorotta I, LaRosa SP, et al. A case of undiagnosed syphilis in a patient undergoing coronary artery bypass graft and aortic valve surgery. Infect Dis Clin Pract 2008; 16(1):76-78.

18.  LaRosa SP, Opal SM. Sepsis strategies in development. Clin Chest Med 2008; 29(4):735­747.

19.  Holubar, M. Connor, M. LaRosa, SP, Singh A. Diagnostic dilemma: The heart of thematter. Am J Med. 2009; 122 (4):335-337.

20.  Laterre PF, Opal SM, Abraham E, LaRosa SP, Creasey AA, Xie F, Poole L,

Wunderink RG. A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (Tifacogin) in patients with severe community-acquired pneumonia. Critical Care 2009; 13(2):R36.

21.  Opal SM, LaRosa SP. Year in Review 2008: Critical care sepsis. Critical Care 2009; 13:224.

22.  Tidswell M, Tillis W, LaRosa SP, et al. Phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist, in patients with severe sepsis. Crit Care Med 2010; 38(1):72-83.

23.  Chan PA, Connell NT, Gabonay AM, Westley B, Larkin JM, LaRosa SP, et al. Oseltamivir resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient. Clin Microbiol Infect 2010; 16(10):1576-1578.

24.  LaRosa SP. Activated protein C for H1N1 influenza? More work to do! Crit Care 2010; 14(3):156.

25.  LaRosa SP, Opal SM. Sepsis Strategies – Old and New. Clin Invest 2011; 1(2):195-210.

26.  LaRosa SP, Opal SM. Biomarkers: The Future. Crit Care Clin 2011; 27(2):407-419.

27.  Wunderink RG, Laterre PF, François B, Perrotin D, Artigas A, Otero Vidal L, Lobo SM,

San Juan J, Hwang SC, Dugernier T, LaRosa S, et al. Recombinant Tissue Factor

Pathway Inhibitor in Severe Community-Acquired Pneumonia: A Randomized Trial. Am. J. Respir. Crit. Care Med 2011 Jun 1; 183(11):1561-1568.

28.  Tidswell M, LaRosa SP. Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis. Expert Rev Anti Infect Ther. 2011; 9(5):507-20.

29.  Kalil AC, LA Rosa SP, Gogate J, Lynn M, Opal SM; the Eritoran Sepsis Study Group. Therapies for Severe Sepsis. Influence of Severity of Illness on the Effects of Eritoran Tetrasodium (E5564) and on Other Therapies for Severe Sepsis. Shock. 2011; 36(4):327-31.

30.  Kalil AC, LaRosa SP. Real-Life Experience with Drotrecogin Alfa (Activated) for Severe Sepsis: An Effectiveness and Safety Meta-analysis and Meta-regression. Lancet ID 2012;12(9):678-86

31.  LaRosa SP, Opal SM. Immune Aspects of Sepsis and Hopes for new therapeutics. Curr Infect Dis Rep. 2012; 14(5):474-83.

32.  White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug- resistant bacterial pathogens. Infectious Diseases Society of America. Clin Infect Dis. 2012;55(8):1031-46

33.  Ranganath S, McGhie TA, LaRosa S, Lehman W, Fader R. Clinical and Laboratory Diagnosis of Central Nervous System Histoplasmosis. Am J Med 2012; 125 (10):e1-e2.

34.  Opal SM, Laterre PF, Francois B, LaRosa SP, et al. A Controlled Clinical Trial of Eritoran, an Antagonist of MD2-TLR4, in Patients with Severe Sepsis: THE ACCESS TRIAL. JAMA 2013;301 (11): 1154-1162

35.  Vincent JL, Ramesh M, Ernest D, LaRosa SP. A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients with Sepsis and Suspected Disseminated Intravascular Coagulation. Crit Care Med. 2013; 41(9):2069-2079.

36.  Opal SM, LaRosa SP. Recombinant Human Activated Protein C as a Therapy for Severe Sepsis: Lessons Learned? Am J Respir Crit Care Med. 2013; 187(10):1041-3.

37.  Bernard GR, Francois B, Mira JP,Vincent JL, Dellinger RP, Russell JA, LaRosa SP, et al. Evaluating the efficacy and safety of two doses of the polyclonal anti-TNF-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled Phase IIb study. Crit Care Med 2014; 42 (3):504-511.

38.  McKrea K, Ward R, LaRosa SP. Removal of Carbapenem-Resistant Enterobacteriaceae (CRE) from Blood by Heparin-Functional Hemoperfusion Media. PLoS One 2014; 9 (12): e114242. doi:10.1371/journal.pone.0114242

39.  Yende S, Austin S, Rhodes A, Finfer S, Opal S, Thompson T, Bozza FA, LaRosa SP, Ranieri M, Angus D. Long-term quality of life among survivors of severe sepsis: analyses of two international trials. Crit Care Med. 2016 Aug; 44(8):1461-7.

40.  Goldschmidt-Clermont PJ, Volinsky FG, LaRosa SP, et al. Time for Well-Powered Controlled Prospective Studies to test a Causal Role for Herpes Viruses in Alzheimer Using Anti-Herpes Drugs. J Gerontol A Biol Sci Med Sci. 2019 Jun 7. pii: glz150. doi: 10.1093/gerona/glz150. [Epub ahead of print]

BOOKS AND BOOK CHAPTERS

1. Tabbarah K, Choueiri T, Tachopoulou O, LaRosa S. 59 year old diabetic man with a painful hand ulcer. In: Longworth DL, Stoller JK, Casey DM, Jewell JK, Eds. Cleveland Clinic Internal Medicine Case Reviews. Philadelphia: Lippincott, Williams and Wilkins, 2003:166­169.

2.      LaRosa SP, Opal SM. Sepsis. Scientific American Textbook of Medicine. (online) 7/2014 http://www.sciammedicine.com/sciammedicine/institutional/tableOfContent.action#

3.    Opal SM, LaRosa SP. The future of diagnosis and treatment for sepsis. Mexican Critical Care Association 2008 (in press).

ABSTRACTS

1.      LaRosa S, Gordon S, Kalmadi S, Truesdell L, Avery R, Arroliga A, Longworth D. Should Prophylaxis for Pneumocystis carinii Pneumonia in Solid Organ Transplant Ever Be Discontinued? 34^th Annual Meeting of the Infectious Diseases Society of America, September 18-20, 1996, New Orleans, LA. Clin Infect Dis 1996; 23(4):902. [Abstract #230]

2.      LaRosa S, Kalmadi S, Longworth D, Truesdell L, Fisher C, Cornish N, Gordon S.

Pneumocystis carinii Pneumonia in Patients without AIDS. 34^th Annual Meeting of the Infectious Diseases Society of America, September 18-20, 1996, New Orleans, LA. Clin Infect Dis 1996; 23(4):902 [Abstract #229].

3.      LaRosa S, Kalmadi S, Longworth D, Truesdell L, Fisher C, Cornish N, Gordon S.

Pneumocystis carinii Pneumonia in Patients without AIDS. 35^th Annual Meeting of the Infectious Diseases Society of America, September 18-20, 1997, San Francisco, CA. Clin Infect Dis 1997; 25:473 [Abstract #640].

4.      Smith K, LaRosa S, Neal J, Winton E, Fisher C. Purpura Fulminans and S.

Pneumoniae Sepsis with Severe Acquired Protein C Deficiency Successfully Treated with Recombinant Human Activated Protein C. XVII Congress of the Intl. Society on Thrombosis and Haemostasis, Washington, DC, August 1999.

5.      LaRosa SP, Opal SM, Utterback B, Yan B, Helterbrand J, Simpson AJ, White N, Fisher CJ. Decreased Protein C, Protein S and Antithrombin III Levels are Predictive of Poor Outcome in Gram-negative Sepsis caused by Burkholderia pseudomallei. Crit Care 2000; 4(suppl. 1): S18.

6.      LaRosa SP, Vincent JL, Bellomo R, et al. Baseline Characteristics of Patients enrolled in

the Phase III trial of rhAPC in Severe Sepsis. The Society of Critical Care Medicine’s 30^th Critical Care Congress, February, 2001.

7.      Bernard GR, Laterre PF, LaRosa SP, et al. The Efficacy and safety of Recombinant Human Activated Protein C for the Treatment of Patients with Severe Sepsis. The Society of Critical Care Medicine’s 30th Critical Care Congress, February 2001.

8.      Dhainaut JF, LaRosa SP, Fisher CJ, Yan SB, Bernard GR for the PROWESS Study Group Effect of Baseline Protein C, Antithrombin and IL-6 Levels on the Mortality Reduction Associated with Recombinant Human Activated Protein C in Patients with Severe Sepsis.American Thoracic Society International Conference, San Francisco, CA, May 18-23, 2001.

9.      Ely EW, LaRosa SP, Helterbrand JD, Bernard GR for the PROWESS Study Group Effect of Age on the Mortality Reduction Associated with Recombinant Human Activated Protein C in Patients with Severe Sepsis. American Thoracic Society International Conference, San Francisco, CA, May 18-23, 2001.

10.  LaRosa SP, Basson B, Dhainaut JF, Kimasewitz G, Opal SM, Drotrecogin Alfa (Activated) Reduces Mortality in Patients with Severe Sepsis Irrespective of Bacterial Pathogen

Classification. 41^st International Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, December 2001.

11.  Garber GE, Opal SM, LaRosa SP, and Maki DG. Fungal Infections as an Important Cause of Severe Sepsis. Focus on Fungal Infections 13, Maui, Hawaii, March 19-21, 2003.

12.  LaRosa SP, Starkey C, Yen-Lieberman B, Annane D, Bellisant E. A pilot study to examine the presence of Cytomegalovirus viremia and its relationship with adrenal function in patients with acute refractory septic shock. Crit Care Med 2003;31(12)suppl:A119

13.  Opal S, Wunderink R, Laterre PF, LaRosa S, Creasey AA, Tobias J. Therapeutic Rationale for Tissue Factor Pathway Inhibitor (TFPI) for Severe Community Acquired Pneumonia

CAP). 42^nd Annual Meeting of the Infectious Diseases Society of America, Boston, MA, September 30-October 3, 2004.

14.  Opal S, Laterre PF, Wunderink R, LaRosa S, Su G, Hua, Y, Mendelson M. Serum Procalcitonin and Prothrombin Fragment 1.2 in Severe CAP: Can Biomarkers Predict

Survival Benefit in Tifacogin Patients? 48^th Annual Interscience Conference on

Antimicrobial Agents and Chemotherapy (ICAAC)/46^th Annual Meeting the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008.

15.  Kalil AC, LaRosa SP. Real-Life Experience with Drotrecogin Alfa Activated for Severe

Sepsis: An Effectiveness and Safety Meta-analysis. 40^th Critical Care Congress, San Diego, CA, January 15-19, 2011. [Abstract 424].

16.  LaRosa SP, Tidswell MA. Comparative Efficacy of Eritoran, a Toll-Like Receptor 4 Antagonist, in Patients with Severe Sepsis and Higher Risk of Mortality by Type of

Causative Pathogen. 40^th Critical Care Congress, San Diego, CA, January 15-19, 2011. [Abstract 428].

17.  LaRosa SP, McCrea K, Ward R. Removal of Cytomegalovirus from blood by Heparin-

functional Hemoperfusion Media. 44^th Critical Care Congress, Phoenix, AZ, January 17-21, 2015. [Abstract 984].

INVITED PRESENTATIONS

1. “Protein C Replacement in Purpura Fulminans”. Emory University School of Medicine,Atlanta, GA, March, 1999

2.    “Potential Use of Activated Protein C as a treatment modality for Microvascular Coagulopathy". DIC Subcommittee, International Society on Thrombosis and Hemostasis, Washington, DC, August, 1999

3.    "The Journey from Academia to Industry and Back Again". Clinical Investigator Training Program, Harvard- MIT Division of Health and Technology, Boston, MA, February, 2000

4.    "Clinical Trials in Sepsis: Historical Lessons and Novel Approaches". Infectious Disease Grand Rounds, Cleveland Clinic Foundation, Cleveland, OH, June, 2000

5.    "Endothelial and Coagulation Dysfunction in Sepsis/MODS". Organ Failure 2000, New York, NY, September, 2000

6.    "Therapeutic Innovations and Controversies in Microcirculatory Dysfunction". Organ Failure 2000, New York, NY, September, 2000

7.    "Baseline Characteristics of Patients enrolled in the Phase III trial of rhAPC in Severe Sepsis". Society of Critical Care Medicine, San Francisco, CA, February, 2001

8.    “Drotrecogin Alfa (Activated) Reduces Mortality in Patients with Severe Sepsis Irrespective of Bacterial Pathogen Classification”. Chicago, IL, December, 2001

9.    “Antibiotics- What’s New”. May Day Therapy-Dermatology, Cleveland, OH. May, 2002

10.            “Sepsis- The Evolving Picture”. Chapman Critical Care Symposium, Akron, OH, May, 2002

11.            “Sepsis”, Combined Medical/Surgical Challenges, Fairview Hospital, Cleveland, OH, November, 2002

12.            “Approach to the Septic Patient”. Infectious Diseases: A Course for Practicing Clinicians, Cleveland, OH, June 2003.

13.            “Current Management of Severe Sepsis and Septic Shock”. Grand Rounds: Infectious Disease Update, The Warren Alpert Medical School of Brown University, Department of Medicine, Providence, RI, April 12, 2005.

14.            "A 58-year-old man with chest pain radiation to his back and new onset lower extremity weakness". Grand Rounds: M&M, The Warren Alpert Medical School of Brown University, Department of Medicine, Providence, RI, July 12, 2005.

15.            “anti-TNF Therapy for Sepsis. Is the Story Over?”. TNF Summit, Cleveland, OH, August, 2005

16.            “Infections Related to Trauma”. Infectious Diseases Fellowship Lecture Series, The Warren Alpert Medical School of Brown University, Providence, RI, February 17, 2006."An 88-year-old man with CMML who presents with progressive weakness and fatigue". Grand Rounds: M&M, The Warren Alpert Medical School of Brown University, Department of Medicine, Providence, RI, February 7, 2006.

17.     "TNF as a specific target in severe sepsis - Is the story over". Grand Rounds: The Warren Alpert Medical School of Brown University, Division of Infectious Diseases, Providence, RI, November 29, 2006.

18.  "A 56-year-old man with fever and recent travel". Grand Rounds: M&M, The Warren Alpert Medical School of Brown University, Department of Medicine, Providence, RI, January 23, 2007.

19.     “A 66-year-old man with six weeks of increasing abdominal girth”. Grand Rounds: M&M, The Warren Alpert Medical School of Brown University, Department of Medicine, Providence, RI, March 13, 2007.

20.     “A 52-year-old man with fevers and chills”. Grand Rounds: M&M, The Warren Alpert Medical School of Brown University, Department of Medicine, Providence, RI, April 10, 2007.

21.     “Purpura Fulminans”. Grand Rounds: Cleveland Clinic Foundation, Division of Infectious Diseases/Vascular Medicine, Cleveland, OH, April 11, 2007.

22.     “Sepsis, Severe Sepsis, and Septic Shock”. American Academy for Clinical Laboratory Science-Central New England (ASCLS-CNE) 58th Annual Clinical Laboratory Science Convention, Microbiology Section, Providence, RI, May 9, 2007.

23.  “Antibiotic Issues in the ICU”. 2008 Update in Critical Care: Implementing Bedside Practice. Rhode Island Hospital and the Miriam Hospital Division of Critical Care Medicine, Providence, RI, June 6, 2008.

24.  "Procalcitonin". Grand Rounds: The Warren Alpert Medical School of Brown University, Division of Infectious Diseases, Providence, RI, September 25, 2008.

25.  “C. Difficile”. 2009 Update in Critical Care: Where are we now and where are we going? Rhode Island Hospital and the Miriam Hospital Division of Critical Care Medicine, Providence, RI, April 17, 2009.

26.  “Sepsis and Septic Shock.” MTC 501, Advanced Clinical Microbiology. University of Rhode Island, Providence, RI, September 16, 2009.

27.  “A 44-year-old woman with abdominal pain and lower extremity rash.” Grand Rounds Panelist: M&M, The Warren Alpert Medical School of Brown University, Department of Medicine, Providence, RI, September 22, 2009.

28.  “Sepsis”. Noon Conference Lecture: The Warren Alpert Medical School of Brown University, Department of Medicine, Providence, Rhode Island, February 2010.

29.  “Biomarkers for Sepsis”. 14^th International Congress on Infectious Diseases(ICID), Miami, FL, March 9-12, 2010.

30.  “Sepsis and Septic Shock”. Grand Rounds: Rhode Island Hospital, Department of Pathology, Providence, RI, May 11, 2010.

31.       ”A 51-year-old female presents with fever and generalized fatigue.” Grand Rounds Panelist: M&M, The Warren Alpert Medical School of Brown University, Department of Medicine, Providence, RI, November 2, 2010.

32.       “Antithrombotics for Sepsis”. Society of Critical Care Medicine (SCCM) 40^th Critical Care Congress, San Diego, CA, January 18, 2011

33.       “Biomarkers for Sepsis: From Readily to Experimental”. Grand Rounds: The Warren Alpert Medical School of Brown University, Division of Infectious Diseases,

Providence, RI, January 20, 2011.

34.       “The Sepsis Disease State”. Medical Grand Rounds, Scott and White Healthcare, Temple, TX, August 5, 2011

35.       “The Future of Sepsis Clinical Research”, Snyder Institute of Infection, Immunity and Inflammation Research Conference, Calgary, Canada, September 5, 2011.

36.       “ACCESS Trial Results”. Society of Critical Care Medicine (SCCM) 41^th Critical Care Congress, Houston, TX, February 6,2012

37.       “Procalcitonin: Pro/Con Debate”. Texas Infectious Disease Society Meeting, San Antonio, TX, June 9^th, 2012.

38.       “Severe Sepsis”, Medical Grand Rounds, Beverly Hospital, Beverly, MA, September 30^th, 2013

39.       “A General Review of Procalcitonin and Utilization in De-escalating Antibiotics”, Fatima Hospital, North Providence, RI, February 6, 2014